News

PipelineReview.com5m
SNIPR BIOME Announces First Patient Dosed in its Phase 1b Clinical Trial of SNIPR001 in Patients with Hematological Cancer
COPENHAGEN, Denmark I June 12, 2025 I SNIPR Biome ApS (“SNIPR”), the company pioneering the development of precision medicines using CRISPR technology for ...
PipelineReview.com5m
Novartis Fabhalta® shows statistically significant and clinically meaningful improvements in hemoglobin in new population of patients with PNH
BASEL, Switzerland I June 12, 2025 I Novartis announced positive results from APPULSE-PNH, a Phase IIIB study evaluating the efficacy and safety of ...
PipelineReview.com17m
SpliceBio Secures $135 Million Series B Financing to Advance Lead Program SB-007 in Stargardt Disease and Expand Pipeline of Genetic Medicines
BARCELONA, Spain I June 11, 2025 I SpliceBio, a clinical-stage genetic medicines company pioneering Protein Splicing to address diseases caused by mutations ...
PipelineReview.com34m
First patient dosed in pivotal Phase 3 REVEAL clinical study of ION582 in Angelman syndrome
In the completed multiple ascending dose (MAD) portion of the Phase 1/2 open-label HALOS study, ION582 provided consistent and encouraging clinical improvement on all functional domains including ...
PipelineReview.com38m
Capsida Receives FDA IND Clearance for Its IV-Administered Gene Therapy for Parkinson’s Disease Associated With GBA Mutations
Capsida is initiating the Phase 1/2 study for CAP-003, with the first patient expected to be dosed in the third quarter of this year ...
PipelineReview.com42m
Samsung Bioepis Presents Long-Term Safety Data of EPYSQLI™ (Eculizumab) in PNH at the European Hematology Association (EHA) Congress 2025
INCHEON, Korea I June 12, 2025 I Samsung Bioepis Co., Ltd. (“Samsung Bioepis”) today presented the long-term safety data of EPYSQLI™ (eculizumab; SB12), a ...
PipelineReview.com1d
Elkedonia closes EUR 11 million seed round to advance neuroplastogens as novel therapeutics for depression and neuropsychiatric disorders
STRASBURG, France and CHARLEROI, Belgium I June 11, 2025 I Elkedonia SAS, a company pioneering a novel neuroplastogen approach to develop therapeutic ...
PipelineReview.com1d
SIFI merges into Faes Farma to become its ophthalmic franchise and expand international access to its portfolio and pipeline
CATANIA, Italy I June 10, 2025 I SIFI, a leading international ophthalmic company, today announced that its shareholders have signed an agreement, subject to ...
PipelineReview.com1d
Bayer and Broad Institute Extend Research Collaboration to Develop New Cardiovascular Therapies
BERLIN, Germany & CAMBRIDGE, MA, USA I June 11, 2025 I Bayer and the Broad Institute today announced that they have extended their research collaboration ...
PipelineReview.com1d
Salipro Biotech and Daewoong Pharmaceutical Announce Collaboration Agreement to Advance Development of Novel Therapeutics
The collaboration combines Salipro Biotech's unique expertise and its Salipro® platform technology to stabilize a challenging drug target and advance ...
PipelineReview.com1d
Antares Therapeutics Launches with $177 Million to Develop First-in-Class Precision Medicines for Cancer and Other Serious Diseases
– Series A financing co-led by Omega Funds, Atlas Venture, Lightspeed Venture Partners, BVF Partners, and Cormorant Asset Management, with participation from other leading healthcare funds – ...
PipelineReview.com1d
Alys Pharmaceuticals announces CTA submission for ALY-301, the first mast cell selective c-Kit inhibitor for treatment of Cold Urticaria
BOSTON, MA, USA and LAUSANNE, Switzerland I June 10, 2025 I Alys Pharmaceuticals, Inc. ("Alys"), an immune-dermatology focused company, today announces the ...